8-K: Oragenics Receives NYSE American Approval for Compliance Plan, Aims to Regain Listing by October 2025

Oragenics has received approval from NYSE American for its plan to regain compliance with listing standards, with a deadline set for October 18, 2025.

Summary

• Oragenics, Inc. was notified by NYSE American on June 18, 2024, that its plan to regain compliance with continued listing standards has been accepted.
• The company's plan addresses how it intends to meet Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide.
• Oragenics has until October 18, 2025, to regain compliance, and will be subject to quarterly monitoring during this period.
• Failure to regain compliance or make sufficient progress may result in delisting proceedings.
• The company's stock will continue to trade on NYSE American under the symbol OGEN with a '.BC' indicator to denote below compliance status.
• The acceptance of the compliance plan does not impact the company's business operations or SEC reporting requirements.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has received approval for its compliance plan, it is still under scrutiny and faces the risk of delisting if it does not meet the requirements by the deadline. The '.BC' indicator on the stock is a negative signal.

Positives

• NYSE American's acceptance of the compliance plan provides Oragenics with a clear path and timeline to regain full listing status.
• The company has been granted a plan period through October 18, 2025, to demonstrate compliance.
• The company's stock will continue to be listed on NYSE American during the plan period, albeit with a compliance indicator.

Negatives

• The company is currently not in compliance with NYSE American's continued listing standards.
• Failure to regain compliance by October 18, 2025, could lead to delisting proceedings.
• The stock will trade with a '.BC' indicator, which may negatively impact investor perception.

Risks

• There is a risk that Oragenics may not be able to regain compliance with NYSE American's listing standards by the deadline.
• The company is subject to quarterly monitoring, and failure to make sufficient progress could trigger delisting proceedings.
• The '.BC' indicator on the stock ticker may negatively affect investor confidence and trading volume.

Future Outlook

Oragenics is focused on regaining compliance with NYSE American listing standards by October 18, 2025, and will be subject to quarterly monitoring during this period. The company's future depends on its ability to meet the requirements of the compliance plan.

Management Comments

• Oragenics is working to regain compliance with NYSE American listing standards.
• The company is focused on developing intranasal pharmaceuticals for neurological disorders.

Industry Context

This announcement is relevant to the biotechnology industry, where companies often face challenges in maintaining listing compliance due to the nature of their development-stage operations. It highlights the importance of financial stability and operational progress for companies listed on major exchanges.

Comparison to Industry Standards

• Many development-stage biotech companies face similar challenges with maintaining listing compliance, particularly those with limited revenue and ongoing research and development costs.
• Companies like Athersys and Ocugen have also faced listing compliance issues, highlighting the common struggles in the biotech sector.
• The timeline of approximately 16 months given to Oragenics to regain compliance is fairly standard in these situations, reflecting the time needed to demonstrate progress.

Stakeholder Impact

• Shareholders are impacted by the potential risk of delisting and the '.BC' indicator on the stock.
• Employees may be affected by the uncertainty surrounding the company's listing status.
• Customers and suppliers may be indirectly affected by the company's financial stability and operational progress.

Next Steps

• Oragenics will be subject to quarterly monitoring by NYSE American.
• The company must make substantial progress towards regaining compliance by October 18, 2025.
• Oragenics will continue to operate its business and report to the SEC as required.

Key Dates

Keywords

NYSE American, listing standards, compliance plan, delisting, Oragenics, OGEN, biotechnology, neurological disorders